Ramyani De

Mrs. Ramyani De

Emory University, Atlanta, Georgia, USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2014 in Journal of Biosciences
Verified
Journal Article
Closed access
PDF file
RDRamyani De
Ramyani De
MMMurali Krishna Mamidi
Murali Krishna Mamidi
GSGurbind Singh
Gurbind Singh
SDSusmita Dutta
Susmita Dutta
IPIshwar S Parhar
Ishwar S Parhar
ADAnjan Kumar Das
Anjan Kumar Das

14 September 2022 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
FAfranck amblard
franck amblard
JLJulia LeCher
Julia LeCher
RDRamyani De
Ramyani De
SGShu Ling Goh
Shu Ling Goh
CLChengwei Li
Chengwei Li
RSRaymond Schinazi
Raymond Schinazi
Coronavirus disease 2019 (COVID-19) is an emerging global pandemic with severe morbidity and mortality caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Molnupiravir, an ester prodrug form of N4-hydroxycytidine (NHC), was recently emergency-use approved for the treatment of early SARS-CoV-2 infections. Herein, we report the synthesis and evaluation of a series of novel NHC analogs.

4 January 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
JLJi-Hoon Lee
Ji-Hoon Lee
JLJulia LeCher
Julia LeCher
EPEric Parigoris
Eric Parigoris
NSNoriyuki Shinagawa
Noriyuki Shinagawa
JSJason Sentosa
Jason Sentosa
STShuichi Takayama
Shuichi Takayama
While breakthroughs with organoids have emerged as next-generation in vitro tools, standardization for drug discovery remains a challenge. This work introduces human airway organoids with reversed biopolarity (AORBs), cultured and analyzed in a high-throughput, single-organoid-per-well format, enabling milestones towards standardization. AORBs exhibit a spatio-temporally stable apical-out morphology, facilitating high-yield direct intact-organoid virus infection. Single-cell RNA sequencing and immunohistochemistry confirm the physiologically relevant recapitulation of differentiated human airway epithelia. The cellular tropism of five severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) strains along with host response differences between Delta, Washington, and Omicron variants, as observed in transcriptomic profiles, also suggest clinical relevance. Dose-response analysis of three well-studied SARS-CoV-2 antiviral compounds (remdesivir, bemnifosbuvir, and nirmatrelvir) demonstrates that AORBs efficiently predict human efficacy, comparable to gold-standard air-liquid interface cultures, but with higher throughput (∼10-fold) and fewer cells (∼100-fold). This combination of throughput and relevance allows AORBs to robustly detect false negative results in efficacy, preventing irretrievable loss of promising lead compounds. While this work leverages the SARS-CoV-2 study as a proof-of-concept application, the standardization capacity of AORB holds broader implications in line with regulatory efforts to push alternatives to animal studies.

16 February 2023 in Viruses
Verified
Journal Article
Open access
PDF file
NBNicolas G. Biteau
Nicolas G. Biteau
SASarah A. Amichai
Sarah A. Amichai
NANiloufar Azadi
Niloufar Azadi
RDRamyani De
Ramyani De
JDJessica Downs-Bowen
Jessica Downs-Bowen
FAfranck amblard
franck amblard
Over the past decades, both 4′-modified nucleoside and carbocyclic nucleoside analogs have been under the spotlight as several compounds from either family showed anti-HIV, HCV, RSV or SARS-CoV-2 activity. Herein, we designed compounds combining these two features and report the synthesis of a series of novel 4′-substituted carbocyclic uracil derivatives along with their corresponding monophosphate prodrugs. These compounds were successfully prepared in 19 to 22 steps from the commercially available (-)-Vince lactam and were evaluated against a panel of RNA viruses including SARS-CoV-2, influenza A/B viruses and norovirus.

22 October 2022 in Microorganisms
Verified
Journal Article
Open access
PDF file
JLJulia LeCher
Julia LeCher
KZKeivan Zandi
Keivan Zandi
VCVivian V. Costa
Vivian V. Costa
FAfranck amblard
franck amblard
STSijia Tao
Sijia Tao
RSRaymond Schinazi
Raymond Schinazi
Yellow fever virus (YFV) is a potentially lethal, zoonotic, blood-borne flavivirus transmitted to humans and non-human primates by mosquitoes. Owing to multiple deadly epidemics, the WHO classifies YFV as a “high impact, high threat disease” with resurgent epidemic potential. At present, there are no approved antiviral therapies to combat YFV infection. Herein we report on 2′-halogen-modified nucleoside analogs as potential anti-YFV agents. Of 11 compounds evaluated, three showed great promise with low toxicity, high intracellular metabolism into the active nucleoside triphosphate form, and sub-micromolar anti-YFV activity. Notably, we investigated a 2′-fluoro,2′-bromouridine phosphate prodrug (C9), a known anti-HCV agent with good stability in human blood and favorable metabolism. Predictive modeling revealed that C9 could readily bind the active site of the YFV RdRp, conferring its anti-YFV activity. C9 displayed potent anti-YFV activity in primary human macrophages, 3D hepatocyte spheroids, and in mice. In an A129 murine model, shortly after infection, C9 significantly reduced YFV replication and protected against YFV-induced liver inflammation and pathology with no adverse effects. Collectively, this work identifies a potent new anti-YFV agent with strong therapeutic promise.

22 April 2024 in Viruses
Verified
Journal Article
Open access
PDF file
SHSelwyn Hurwitz
Selwyn Hurwitz
RDRamyani De
Ramyani De
JLJulia LeCher
Julia LeCher
JDJessica A. Downs-Bowen
Jessica A. Downs-Bowen
SGShu Ling Goh
Shu Ling Goh
RSRaymond Schinazi
Raymond Schinazi
Most repurposed drugs have proved ineffective for treating COVID-19. We evaluated median effective and toxic concentrations (EC50, CC50) of 49 drugs, mostly from previous clinical trials, in Vero cells. Ratios of reported unbound peak plasma concentrations, (Cmax)/EC50, were used to predict the potential in vivo efficacy. The 20 drugs with the highest ratios were retested in human Calu-3 and Caco-2 cells, and their CC50 was determined in an expanded panel of cell lines. Many of the 20 drugs with the highest ratios were inactive in human Calu-3 and Caco-2 cells. Antivirals effective in controlled clinical trials had unbound Cmax/EC50 ≥ 6.8 in Calu-3 or Caco-2 cells. EC50 of nucleoside analogs were cell dependent. This approach and earlier availability of more relevant cultures could have reduced the number of unwarranted clinical trials.